Work

Comment on ‘Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years’: clarifying drug survival metrics and capturing joint outcomes

Year: 2026

Type: letter

Abstract: Comment on ‘Drug survival, effectiveness and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years’ by Mastorino et al. Clarifying the handling of nonmedical discontinuations and providing additional insight into outcomes among patients with concomitant psoriatic arthritis could further strengthen the external comparability and clinical interpretability of the reported drug survival.

Source: Clinical and Experimental Dermatology

DOI: 10.1093/ced/llag024

Authors: Jiuyuan Qin, Jie Deng, Yulin Zou

Institutions: Dalian Medical University, Second Affiliated Hospital of Dalian Medical University, Universitätsmedizin Göttingen, University of Göttingen

Language: English

Topic: Psoriasis: Treatment and Pathogenesis

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7124809068

Cites:

Cited by:

Related to: